Explore approved biosimilar medicines
| # | Medicine | Status | Active Substance | Therapeutic Area | Developer | Published Date |
|---|---|---|---|---|---|---|
| 121 | Vgenfli | Authorised | aflibercept | Wet Macular Degeneration;Macular Edema;Diabetes Complications;Retinal Vein Occlusion;Choroidal Neovascularization | Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A. | 20-06-2025 |
| 122 | Amsparity | Authorised | adalimumab | Arthritis, Rheumatoid;Arthritis, Psoriatic;Psoriasis;Spondylitis, Ankylosing;Uveitis;Hidradenitis Suppurativa;Colitis, Ulcerative;Crohn Disease;Arthritis, Juvenile Rheumatoid | Pfizer Europe MA EEIG | 14-02-2020 |
| 123 | Herwenda | Authorised | trastuzumab | Breast Neoplasms;Stomach Neoplasms | Sandoz GmbH | 15-09-2023 |
| 124 | Zadenvi | Authorised | denosumab | Bone Resorption;Osteoporosis;Osteoporosis, Postmenopausal | Zentiva k.s. | 25-04-2025 |
| 125 | Rixathon | Authorised | rituximab | Lymphoma, Non-Hodgkin;Arthritis, Rheumatoid;Leukemia, Lymphocytic, Chronic, B-Cell;Wegener Granulomatosis;Microscopic Polyangiitis;Pemphigus | Sandoz GmbH | 12-07-2018 |
| 126 | Tyenne | Authorised | tocilizumab | Arthritis, Rheumatoid;Cytokine Release Syndrome;Arthritis, Juvenile Rheumatoid;COVID-19 virus infection;Giant Cell Arteritis | Fresenius Kabi Deutschland GmbH | 07-08-2023 |
| 127 | Zefylti | Authorised | filgrastim | Neutropenia;Hematopoietic Stem Cell Transplantation;Cancer | CuraTeQ Biologics s.r.o | 13-12-2024 |
| 128 | Truxima | Authorised | rituximab | Lymphoma, Non-Hodgkin;Arthritis, Rheumatoid;Wegener Granulomatosis;Leukemia, Lymphocytic, Chronic, B-Cell;Microscopic Polyangiitis | Celltrion Healthcare Hungary Kft. | 17-05-2018 |
| 129 | Blitzima | Authorised | rituximab | Lymphoma, Non-Hodgkin;Leukemia, Lymphocytic, Chronic, B-Cell | Celltrion Healthcare Hungary Kft. | 17-05-2018 |
| 130 | Bomyntra | Authorised | denosumab | Neoplasms, Bone Tissue;Giant Cell Tumor of Bone | Fresenius Kabi Deutschland GmbH | 23-05-2025 |
Ready to transform your strategic intelligence? Let's talk
Get latest pharmaceutical insights, blogs, and strategic updates directly in your inbox.